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Purpose. To investigate whether absolute value of procalcitonin (PCT) or the change (delta-PCT) is better indicator of infection in
intensive care patients.Materials and Methods. Post hoc analysis of a prospective observational study. Patients with suspected new-
onset infection were included in whom PCT, C-reactive protein (CRP), temperature, and leukocyte (WBC) values were measured
on inclusion (𝑡
0
) and data were also available from the previous day (𝑡
−1
). Based on clinical and microbiological data, patients were
grouped post hoc into infection- (I-) and noninfection- (NI-) groups. Results. Of the 114 patients, 85 (75%) had proven infection.
PCT levels were similar at 𝑡
−1
: I-group (median [interquartile range]): 1.04 [0.40–3.57] versus NI-group: 0.53 [0.16–1.68], 𝑝 = 0.444.
By 𝑡
0
PCT levels were significantly higher in the I-group: 4.62 [1.91–12.62] versus 1.12 [0.30–1.66], 𝑝 = 0.018. The area under the
curve to predict infection for absolute values of PCT was 0.64 [95% CI = 0.52–0.76], 𝑝 = 0.022; for percentage change: 0.77 [0.66–
0.87], 𝑝 < 0.001; and for delta-PCT: 0.85 [0.78–0.92], 𝑝 < 0.001. The optimal cut-off value for delta-PCT to indicate infection
was 0.76 ng/mL (sensitivity 80 [70–88]%, specificity 86 [68-96]%). Neither absolute values nor changes in CRP, temperature, or
WBC could predict infection. Conclusions. Our results suggest that delta-PCT values are superior to absolute values in indicating
infection in intensive care patients. This trial is registered with ClinicalTrials.gov identifier: NCT02311816.
1. Introduction
Treatment of severe sepsis and septic shock remains a major
challenge in the critically ill, and it is still one of the leading
causes of death worldwide [1]. Despite increased awareness
of the importance of early resuscitation, mortality in North
America and Europe ranges between 28 and 41% [2]. Based
on a consensus agreement sepsis is defined as infection in
the presence of systemic inflammatory response syndrome
(SIRS) [3]. However, the signs of SIRS are nonspecific and can
often be seen in several (none septic) critically ill conditions.
Fever, tachycardia, or leukocytosis on their own has low
sensitivity and specificity [4, 5]. Detailed microbiological
results are often only available after 24 hours or later, and
negative results do not necessarily rule out infection. Nev-
ertheless, early diagnosis of infection in critically ill patients
is of utmost importance, and delay in starting appropriate
antibiotic therapymay lead to lethal events [6]. However, giv-
ing antibiotics unnecessarily to every acutely ill patient is an
unacceptable practice for several reasons [7]. Therefore, fast
reacting biomarkers of infection have been used for almost 50
years to help the clinician, of which C-reactive protein (CRP)
and procalcitonin (PCT) are the most often used and studied
[8].
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Procalcitonin is a fast reacting biomarker with a half-
life of around 24 hours [9]. Its sensitivity and specificity for
bacterial infection seem to be superior compared to CRP
[10, 11]. However, itmust be considered that the same absolute
values of PCT cannot be used in all circumstances. It has been
reported that PCT levels are higher in surgical compared to
medical patients [12], and elevated PCT can also be present
without infection, in conditions such as trauma [13] and
surgery [14] or after cardiac arrest [15].There is some evidence
that evaluating PCT kinetics may be superior to absolute
values [12, 16].
In this study, our aim was to investigate whether the
absolute value of PCT measured in critically ill patients on
the day when infection was suspected, or the change in PCT
(delta-PCT) from the day before to the day when infection
was suspected, was a better indicator of infection.
2. Methods
2.1. Patient Selection. This prospective observational study
was part of the Early Procalcitonin Kinetics (EProK) study,
which was undertaken between October 2012 and October
2013 and approved by the Regional and Institutional Human
Medical Biological Research Ethics Committee, University
of Szeged, Hungary (WHO-3005; 19.04.2012, Chairperson
Professor T. Wittmann). A detailed description of the EProK
study and the final results are published elsewhere [17].
The investigation was performed at the University of Szeged
(Szeged, Hungary), Albert Szent-Gyo¨rgyi Health Center
in four tertiary intensive care units. The study was reg-
istered at ClinicalTrials.gov with the registration number:
NCT02311816. Written informed consent was obtained from
all subjects or from their relatives.
2.1.1. Inclusion Criteria. In the EProK study all patients over
18 years with suspected infection on admission or during
their stay on the intensive care unit were screened for eligibil-
ity. Patients were enrolled, when the attending intensive care
specialist suspected infection, based on (1) suspected source
which could be identified, (2) new onset organ dysfunction,
and (3) body temperature, PCT, CRP, and the decision to start
empirical antibiotic therapy. Once the original EProK study
was completed, in a post hoc analysis those patients in whom
PCT and CRP values were available from the previous day
(𝑡
−1
) were included in the current analysis.
2.1.2. Exclusion Criteria. Exclusion criteria included patients
younger than 18 years, who had received antibiotic therapy
in the previous 48 hours, and those who received acute renal
replacement therapy 24 hours before enrollment. Patients
were also excluded following cardiopulmonary resuscitation
and with end stage diseases with a “do not resuscitate”
order. Immunocompromised patients (human immunodefi-
ciency virus infection, bone marrow transplantation, malig-
nant haematological disorders, and chemotherapy) were also
excluded.
2.2. Subgroups and Definitions. Diagnosis of infection was
based on a post hoc analysis of mainly microbiological results
but also clinical parameters and biochemical results which
were evaluated by two experts (infectologist, EH, and an
intensivist, FJ) blinded for the PCT data apart from the first
PCT measurement (𝑡
0
, see below). The experts also took into
consideration the recommendations of international guide-
lines [18, 19]. Based on these results, patients were grouped
into “infection-” (I-) and “noninfection-” (NI-) groups.
For subgroup analysis, patients were divided into “med-
ical” and “surgical” groups. The medical-group represented
patients who had had no surgical intervention before and
during the study period and for source control did not require
surgery. In the surgical-group infection either was related to
an operation or required surgery for source control [12].
2.3. Protocol and Data Collection. Whenever infection was
suspected by the attending physician, the signs of infection
and the suspected source were recorded, which included
high/low body temperature (<36∘C; >38∘C), high/low white
blood cell count (<4,000; >12,000 million/mL), acute wors-
ening of the clinical picture (hemodynamic instability, wors-
ening PaO
2
/FiO
2
ratio, and deterioration in mental status or
any other clinical sign indicating infection). Microbiological
specimens were collected from all suspected sources immedi-
ately before the administration of the first dose of antibiotics
(𝑡
0
).
2.3.1. Data Collection. After enrollment, demographic data,
signs of infection, the suspected source of infection, and
corresponding microbiological samples were registered. The
length of intensive care unit and hospital stay, 28 days, and
the overall mortality were also documented.
2.3.2. Procalcitonin Measurement. It is common practice in
our ICU to measure PCT daily in critically ill patients. Pro-
calcitonin levels were documented from the previous day of
enrollment (𝑡
−1
) and immediately before the initiation of ABs
(𝑡
0
). Core temperature, C-reactive protein (CRP), and white
blood cell count (WBC) were also recorded with every PCT
measure. The flow chart of the data collection is summarised
in Figure 1.
Serum PCT levels were measured with Cobas 6000
analyzer (Hitachi High-Technologies Corporation, Tokyo,
Japan). Analyzer reagents (Elecsys B⋅R⋅A⋅H⋅M⋅S PCT assay)
were developed in collaboration with B⋅R⋅A⋅H⋅M⋅S cor-
poration (Hennigsdorf, Germany) and Roche Diagnostics
(Mannheim, Germany). Procalcitonin was determined by
electrochemiluminescence immunoassay (ECLIA) serum on
the automated Roche Elecsys and Cobas immunoassay ana-
lyzers.
2.3.3. Microbiological Staining and Antibiograms. Microbio-
logical tests were performed and sent at 𝑡
0
, before the first
antibiotic dose was administered and if needed they were
repeated on the following days, to identify infection.
2.4. Statistical Analysis. Data were analyzed using IBM SPSS
Statistics Version 20 (Armonk, NY, USA) and Systat Software
Inc. SigmaPlot 12.5 (London, UK) software. For continuous
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Figure 1: Flow chart.
data, the Shapiro-Wilk tests were performed to assess nor-
mal distribution. Demographic data were analyzed between
groups with Student’s 𝑡-test or nonparametric data with
the Mann-Whitney 𝑈 test as appropriate. Categorical data
were compared using 𝜒2 tests. Biomarkers were analyzed
by using Two-Way Repeated Measures Analysis of Variances
(All Pairwise Multiple Comparison Procedures: Holm-Sidak
method). Logistic regression, receiver operating characteris-
tic (ROC) curve, and the respective areas under the curves
(AUC) were calculated for PCT, CRP, body temperature,
and white blood cell count levels. The best cut-off values
were determined using the Youden index (𝐽 = max[Sens +
Spec−1]).The test parameters (sensitivity, specificity, positive,
and negative predictive values) were compared by their 95%
confidence intervals. Logistic regression analysis was used to
determine the best combination of parameters and cut-offs
for predicting infection. The level of 𝑝 < 0.05 was defined
as statistically significant. Data are given as mean ± standard
deviation or median (interquartile range) as appropriate.
The “delta” was considered as the changes in the absolute
values (subtracting 𝑡
−1
from 𝑡
0
); the percentage values were
calculated as [(𝑡
0
/𝑡
−1
) × 100 − 100].
3. Results
Over the one-year study period all ICU patients were
screened for eligibility and 209 patients were recruited into
the EProK study. Out of the 209 patients in the current
post hoc analysis we include 114 cases where PCT values
were available from the previous day. Demography and out-
comes characteristics for the entire cohort are summarised
in Table 1. Out of the 114 patients, 85 (75%) patients were
identified as having proven infection and in 29 (25%) patients
the presence of infection was highly unlikely. Disease severity
scores and outcomes were similar in the two groups, but the
NI-group required less organ support.
The clinical and laboratory signs of infection on which
the clinicians suspected infection at the time of inclusion (𝑡
0
)
are summarised in Table 2. Although all indices were higher
in the I-group, but only the altered level of consciousness,
hemodynamic instability, and the PCT was significantly
different between the two groups.
Regarding the suspected source of infection, generally
there was nonsignificant difference between the groups, but
significantly more patients were suspected of having abdomi-
nal related infection in theNI-group.Detailed data on the iso-
lated pathogens and their sources are summarised in the Sup-
plemental Digital Content Tables S5–7 (see Supplementary
Material available online at http://dx.doi.org/10.1155/2016/
3530752).
3.1. PCT, CRP, WBC, and Temperature Values at 𝑡
−1
and 𝑡
0
3.1.1. Total Sample. Measurement results at 𝑡
−1
and 𝑡
0
in
the I- and NI-groups are shown in Figure 2. PCT absolute
values were similar at 𝑡
−1
, but by 𝑡
0
in the I-group levels were
significantly higher compared to the NI-group and there was
also a significant increase from 𝑡
−1
, while there was no such
change in theNI-group.Therewas no significant difference in
CRP and WBC count between the two groups nor could we
find significant changes from 𝑡
−1
to 𝑡
0
.Therewas nodifference
between the groups for body temperature but there was a sta-
tistically significant increase in theNI-group by 𝑡
0
. It is of note
that body temperature remained <38∘C in almost all patients.
3.1.2. Medical and Surgical Patients. Measurement results in
medical (𝑛 = 80) and surgical (𝑛 = 34) patients are sum-
marised inTable 3. In the surgical subgroupPCTabsolute val-
ues were significantly higher than in the medical cohort, but
the pattern of change was similar. In the NI-group there was a
slight, but statistically significant increase in medical patients
from 𝑡
−1
to 𝑡
0
, while there was no significant change in surgi-
cal patients, where levels actually decreased slightly. However,
in the I-group there was an almost 3-fold increase in the PCT
levels.
Regarding the CRP, body temperature, and WBC count,
there was no significant changes over time and no differences
between medical and surgical patients.
3.2. Predictive Value for Indicating Infection. The predictive
value for infection for the absolute values of PCT, CRP,
temperature, and WBC count can be seen in Figure 3 and is
summarised in Table 4. Only PCT had a significant predictive
value, but with a poor AUC (Figure 3). However, regarding
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Table 1: Demographics, organ support, and outcome in the entire cohort.
Total NI-group I-group 𝑝 value
Age (years) 65 (22.5) 67 (25.5) 65 (22) 0.772
Gender (M/F) 69/45 15/14 54/31 0.261
Body height (cm) 170 (12) 167 (19) 170 (11) 0.766
Body weight (kg) 73 (25) 80 (25) 70 (20) 0.345
SAPS II points 62.2 ± 20.5 62.7 ± 25.5 66.1 ± 18.6 0.513
SAPS II PM (%) 77.2 (52.1) 64.0 (75.9) 78.5 (42.1) 0.437
ICU days before enrollment 1 (3) 1 (3) 1 (3) 0.669
Mechanical ventilation 80 (70.2%) 12 (41.4%) 68 (80.0%) <0.001
Vasopressor therapy 69 (60.5%) 13 (44.8%) 56 (65.9%) 0.045
ICU LOS (day) 9 (12) 8 (8) 9 (12) 0.089
ICU survival 84 (73.7%) 24 (82.8%) 60 (70.6%) 0.199
Hospital LOS (day) 17 (20) 14 (17) 19 (22) 0.050
Hospital survival 67 (58.8%) 20 (68.9%) 47 (55.3%) 0.197
28-day survival 64 (56.1%) 19 (65.5%) 45 (52.9%) 0.239
Data are given as mean ± standard deviation or median (interquartile range) as appropriate. M: male; F: female; SAPS: simplified acute physiology score; PM:
predicted mortality; ICU: intensive care unit; LOS: length of stay; mechanical ventilation and vasopressor therapy represent data at the day of enrollment.
Table 2: Clinical signs and suspected source of infection at enrollment (𝑡
0
).
Total
𝑛 = 114
NI-group
𝑛 = 29
I-group
𝑛 = 85
𝑝 value
Fever (<36∘C; >38∘C) 55 (48.2%) 13 (44.8%) 42 (49.4%) 0.670
WBC (>12 or <4 × 109/L) 82 (71.9%) 22 (75.9%) 60 (70.6%) 0.585
Impaired gas exchange 82 (71.9%) 18 (62.1%) 64 (75.3%) 0.171
Impaired consciousness 59 (51.8%) 9 (31.0%) 50 (58.8%) 0.010
Hemodynamic instability 74 (64.9%) 13 (44.8%) 61 (71.8%) 0.009
PCT (ng/mL) 3.37 (9.22) 1.12 (1.36) 4.62 (10.72) 0.018
CRP (mg/L) 182.75 (158.5) 147.60 (156.50) 208.80 (140.60) 0.301
Respiratory 72 (63.2%) 17 (58.6%) 55 (64.7%) 0.557
Soft tissue 13 (11.4%) 2 (6.9%) 11 (12.9%) 0.377
Abdominal 14 (12.3%) 7 (24.1%) 7 (8.2%) 0.024
Urinary tract 5 (4.4%) 0 5 (5.9%) 0.182
Bloodstream 6 (5.3%) 2 (6.9%) 4 (4.7%) 0.648
Central nervous system 4 (3.5%) 1 (3.4%) 3 (3.5%) 0.984
WBC: white blood cell count, PCT: procalcitonin, and CRP: C-reactive protein. The PCT and CRP values are presented as median (interquartile range).
Table 3: PCT, CRP, body temperature, and white blood cell count in medical and surgical patients with and without infection.
NI-group I-group
𝑡
−1
𝑡
0
𝑡
−1
𝑡
0
Medical
PCT (ng/mL) 0.26 (0.57) 0.54 (1.16)∗ 0.89 (1.52) 3.17 (5.9)∗#
CRP (mg/L) 136.7 (159.1) 141 (125.9) 150 (184.3) 164.2 (145.3)
BT (∘C) 36 (1.02) 37 (0.82)∗ 36.9 (1.23) 37 (1.6)
WBC (×109/L) 14.32 (8.9) 15.4 (8.64) 12.06 (6.36) 13.76 (10.16)
Surgical
PCT (ng/mL) 3.5 (9.91) 2.89 (9.33) 3.83 (22.55) 14.9 (58.06)∗#
CRP (mg/L) 95 (342.5) 163 (327.4) 199.5 (130.1) 243.2 (112.7)
BT (∘C) 36.5 (2) 36.5 (2.4) 36 (1) 36.9 (1.1)
WBC (×109/L) 8.99 (7.37) 14.56 (9.65) 11.9 (10.06) 10.91 (9.9)
Data are presented as median (interquartile range). PCT: procalcitonin, CRP: C-reactive protein, BT: body temperature, and WBC: white blood cell count;
∗𝑝 < 0.05 within groups and #𝑝 < 0.05 between groups.
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Figure 2: PCT, CRP, body temperature, and WBC count absolute values in the total cohort. Boxplots present median (interquartile range)
10th and 90th percentile. ∗ indicates 𝑝 < 0.05.
Table 4: The predictive value of the absolute values, percentage, and delta changes of PCT, CRP, temperature, and WBC count for infection
in the total cohort.
Absolute value Percentage changes Absolute value changes
AUC 95% CI 𝑝 value AUC 95% CI 𝑝 value AUC 95% CI 𝑝 value
Total
PCT 0.64 0.52–0.76 0.022 0.77 0.66–0.87 <0.001 0.85 0.78–0.92 <0.001
CRP 0.60 0.47–0.72 0.103 0.54 0.41–0.66 0.530 0.54 0.42–0.65 0.536
BT 0.52 0.39–0.63 0.804 0.56 0.44–0.68 0.300 0.56 0.44–0.68 0.322
WBC 0.60 0.48–0.70 0.125 0.51 0.40–0.61 0.852 0.51 0.39–0.61 0.924
Medical
PCT 0.67 0.54–0.80 0.016 0.76 0.63–0.88 <0.001 0.83 0.73–0.92 <0.001
CRP 0.58 0.44–0.72 0.248 0.57 0.42–0.70 0.359 0.57 0.44–0.70 0.306
BT 0.51 0.37–0.64 0.858 0.64 0.50–0.77 0.055 0.64 0.49–0.77 0.060
WBC 0.57 0.44–0.70 0.329 0.56 0.43–0.68 0.441 0.57 0.43–0.69 0.365
Surgical
PCT 0.78 0.58–0.97 0.025 0.80 0.59–1.00 0.014 0.94 0.85–1.00 <0.001
CRP 0.56 0.23–0.87 0.654 0.56 0.29–0.81 0.654 0.54 0.31–0.76 0.749
BT 0.52 0.22–0.80 0.898 0.63 0.39–0.85 0.306 0.63 0.39–0.86 0.296
WBC 0.63 0.44–0.82 0.277 0.67 0.47–0.86 0.166 0.71 0.49–0.90 0.108
AUC: area under the ROC curve, CI: confidence interval, PCT: procalcitonin, CRP: C-reactive protein, BT: body temperature, andWBC:white blood cell count.
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Figure 3: The predictive value of the absolute values, percentage, and delta changes of PCT, CRP, temperature, andWBC count for infection
in the total cohort.
the percentage and delta changes CRP, temperature andWBC
counts diagnostic value did not change, while PCT’s AUC for
both percentage and delta changes had a significantly better
performance for predicting infection. Similar patterns were
observed in the medical and surgical subgroups (Table 4).
3.3. Best Cut-Off Value. The best cut-off values were defined
for PCT only as there was no significant predictive value for
the other parameters, as determined by the Youden index. For
the PCT absolute value it was 0.84 ng/mL with a sensitivity of
61% (95% CI: 50–72) and specificity 72% (53–87) to indicate
infection in the ICU. Regarding the percentage change a PCT
increase of >88% from 𝑡
−1
to 𝑡
0
had a sensitivity of 75% (65–
84) and specificity of 79% (60–92) and a PCT delta change of
>0.76 ng/mL had a sensitivity of 80% (70–88) and specificity
of 86% (68–96) to indicate infection.
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Data were also analyzed using the logistic regression
model for finding the best combination of these four param-
eters together to predict infection in the ICU. However, none
of the combinations tested improved the performance for
predicting infection (data not shown).
4. Discussion
Themain finding of this observational study was an increase
in PCT levels from the day before (𝑡
−1
) to the day when
infection was suspected (𝑡
0
) predicted infection, while in
patients with no proven infection PCT remained unchanged.
Furthermore, regarding the conventional indicators of infec-
tion such as WBC, body temperature, and CRP, neither the
absolute values nor their change from 𝑡
−1
to 𝑡
0
could predict
infection.
Diagnosing infection in the critically ill is challenging.
Appropriate decision making has paramount importance as
any delay in adequate antibiotic treatment of sepsis and septic
shock evokes worsening morbidity and mortality results [6,
20]. On the other hand unnecessary antibiotic administration
in patients without infection has led to the emergence of
multidrug-resistant bacteria [21, 22], complications related to
the side effects of the antibiotics themselves and an increased
burden of healthcare expenses [23]. Despite its importance,
there is no gold standard for diagnosing/proving infection in
the critical care setting.
In our study 75% of patients had proven infection. This
complex post hoc analysis of all results is fundamentally
different from “labelling” patients as septic, based solely on
the Surviving Sepsis Guideline criteria at the time of initial
assessment as seen in several studies [24, 25]. Although our
method also has some uncertainties, it provides amore robust
approach utilising all data, clinical, biochemical, and micro-
biology alike, to aid in the diagnosis of patients with bacterial
infection. However, it is also important to acknowledge that
there is no gold standard to diagnose infection; therefore
despite all our efforts, some patients in the NI-group may
have had culture negative infection.
In our investigation it was found that conventional
indicators of infection such as body temperature and white
cell count had less value in diagnosing infection. Levels
of WBC count remained elevated on both days and there
was no significant change over time. This phenomenon can
be explained by the nonspecific activation of the immune
cascade as often seen in ICU patients [26]. Although there
was a statistically significant increase in body temperature in
theNI-group, levels largely remained below 38∘C in almost all
patients. These results are in accordance with recent findings
that increased temperature alone does not predict infection
[27].
Although microbiology remains the gold standard for
confirming pathogens, results only come back at least 24–48
hours after sampling. Furthermore, in several cases results
remained negative, despite obvious signs of infection. In
order to help the diagnostic process several novel biomarkers
of infection have been developed [8].However, all biomarkers
share the same limitations that “one size will not fit all,” due
to the complex pathomechanism and the heterogeneity of
patients.
The twomost commonly usedmarkers in infection/sepsis
diagnostics are PCT and CRP [8]. Procalcitonin is detectable
in the serum a few (2–4) hours after the onset of bacterial
infection. It reaches its peak within 24 hours and then starts
to decline with adequate treatment by around a 50% daily
decrease according to its half-life [9]. In contrast, CRP has a
delayed response. It reaches its maximum value usually after
48 hours of an insult and in general it lags behind the actual
events of the inflammatory and clinical process. Furthermore,
CRP levels are generally elevated inmost ICUpatients regard-
less of the aetiology. In our study neither the absolute values
of CRP nor its delta changes were able to indicate new onset
infection. Patients had elevated CRP values with a median
of almost 200mmol/L for the whole cohort, which makes
interpretation very difficult. Furthermore the kinetics did not
show any significant change over time. Therefore, our results
question the place of CRP measurements for diagnosing
infection on the ICU.
The most important finding of the current study was to
show the superiority of PCT kinetics over the absolute values
to indicate new onset infection in the ICU. However, this
requires at least daily measurements of PCT, which has been
common practice in our ICU in critically ill patients in whom
infection cannot be excluded. Our current findings are in
accordance with those reported by Tsangaris et al. [16]. They
also measured PCT daily and observed a twofold increase of
PCT levels from the day before to the day when there was a
sudden onset of fever in patientswith proven infection, but no
change in PCT was found in patients without infection.They
concluded that, in patients treated chronically in the ICU,
PCTvalues on the day of fever onsetmust be compared to val-
uesmeasured the previous day in order to define whether this
rise in temperature was due to infection or not. An important
difference between their and our study is that in our patients
body temperature merely reached 38∘C; in fact most of these
patients were apyrexial, despite 75% having proven infection.
Therefore, we recommend to evaluate PCT kinetics not only
in the onset of fever, but whenever infection is suspected on
the ICU. Based on the current results, the best cut-off values
were also determined for change in PCT, which were >88%
and>0.76 ng/mL delta change from 𝑡
−1
to 𝑡
0
.The reasonswhy
a given absolute value of any biomarker, not just PCT, may be
of limited value as compared to its changes can be explained
by the pathomechanism of systemic inflammation. It was a
very important discovery that after trauma, burns, ischemia-
reperfusion, pancreatitis, major surgery, and so forth, the
same or similar molecules are released predominantly from
the mitochondria, as after an infectious insult. Based on
aetiology these are called “damage-associated molecular
patterns” (DAMP), or “pathogen associated molecular pat-
terns” (PAMP). Once similar mediators/proteins are released
they act on the same receptors of monocytes inflicting a
similar inflammatory response, including PCT release and
subsequent organ dysfunction [28, 29].
Indeed, PCT levels were found to be severalfold higher
in surgical compared to medical patients in septic shock
despite the similar clinical manifestation and severity of
8 Journal of Immunology Research
the clinical picture [12]. This explains why PCT levels were
elevated in our surgical patient population without proven
infection, with median values of around 3.5 (NI-group)
and 3.8 (I-group) ng/mL at 𝑡
−1
. The corresponding PCT
values in medical patients were substantially lower (0.26 and
0.89 ng/mL, resp.). Although levels were higher in the I-group
at 𝑡
−1
, this difference did not reach statistical significance
while there was a severalfold increase in the I-group in both
medical and surgical patients with no change in kinetics in
the NI-groups.
In two large recent multicenter trials the authors could
not showany benefit fromaPCT-based approach in antibiotic
management in the ICU [30, 31]. However, in both studies
the threshold for intervention was a PCT of >1 ng/mL. As
40% of the patients in both trials were surgical, in whom
this threshold for intervention may be too low, one cannot
exclude that these patients may have had received antibiotics
unnecessarily. This overuse of antibiotics may be one of the
reasons for the worse outcome in the PCT-guided group
in both studies. Our study provides further evidence that
changes or kinetics of PCTmaybe superior to absolute values.
The current study has several limitations. Firstly, onemay
argue that there was a selection bias; in other words, physi-
cians suspected infection more often when they observed a
PCT increase in a patient. Although this cannot be excluded
completely, at the time when the study was performed,
PCT collection was not the routine practice within the
department, and delta-PCT was not included among the
criteria of inclusion either. The whole idea of retrieving PCT
data from the day before came after we analyzed the original
EProK database. Secondly, despite all our efforts of allocating
patients into the I- and NI-groups, this took place in a post
hoc fashion. The available clinical results were analyzed in
a blinded manner for delta-PCT (apart from PCT values
at 𝑡
0
) and thoroughly by our experts; however, one cannot
exclude the possibility of inappropriate judgment during the
decision making. The lack of gold standard for diagnosing
infection is aggravated by this obscurity when configuring
groups. Furthermore, the sample size was generally small,
especially to be able to draw firm conclusions regarding
the medical, surgical subgroups, although the trend in our
results was certainly promising. Finally, it remains uncertain
why PCT values were measured on the previous day before
starting empiric antibiotic therapy in more than 50% of the
209 patients of the EProK study. Therefore, some selection
bias cannot be excluded. The median day of inclusion into
the study from ICU admission was 1 day, indicating that 50%
of patients had PCT measurements on the ward/Accident
and Emergency Unit, before admission. However, this may
also reinforce the importance of measuring PCT values
consecutively.
5. Conclusion
The main finding of this observational study was that an
increase in PCT levels from the day before (𝑡
−1
) to the
day when infection was suspected (𝑡
0
) predicted infection,
while in patients with no proven infection PCT remained
unchanged. Based on the data presented a single PCT
measurement may not be adequate to differentiate between
an infectious and noninfectious inflammatory response.This
means that the kinetics of procalcitonin values based on daily
measurements are superior to absolute values in diagnosing
infection on the ICU and absolute values of procalcitonin
may be of limited use. Both absolute values and kinetics of
C-reactive protein are poor indicators of infection; further-
more, conventional indicators of infection such as white cell
count and body temperature have limited use for predicting
infection in the ICU.Theclinical implication of these results is
that daily PCTmeasurements in patients at high risk of infec-
tion allow the opportunity to evaluate PCT kinetics, which
may improve diagnostic accuracy and rationalise antibiotic
therapy on the ICU and improve outcome.
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